Monotherapy of ceftazidime–avibactam and ceftolozane–tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates

Bibliographic Details
Main Author:	Benjamin Davido
Format:	Article
Language:	English
Published:	Elsevier 2017-09-01
Series:	International Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971217301765

Monotherapy of ceftazidime–avibactam and ceftolozane–tazobactam against multidrug-resistant organisms
by: Adnan Alatoom
Published: (2017-09-01)

Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
by: Claire Rempenault, et al.
Published: (2021-06-01)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016-12-01)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020-02-01)

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
by: Adnan Alatoom, et al.
Published: (2017-09-01)

In Vitro Activity of Ceftolozane/tazobactam and Ceftazidime/avibactam Against Carbapenemase-producing Pseudomonas aeruginosa
by: Özlem AYDEMİR, et al.
Published: (2019-12-01)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020-09-01)

Antimicrobial susceptibility of multi-drug and extensively-drug-resistant Escherichia coli to ceftolozane-tazobactam and ceftazidime-avibactam: An in vitro study*
by: Patrycja Zalas-Więcek, et al.
Published: (2020-04-01)

Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
by: Louie Mar Gangcuangco, et al.
Published: (2016-01-01)

Integrated Genome-Wide Analysis of an Isogenic Pair of <i>Pseudomonas aeruginosa</i> Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam
by: Weihua Huang, et al.
Published: (2020-02-01)

Evaluation of In Vitro Activity of Ceftolozane-tazobactam and Ceftazidime-avibactam Against Carbapenemase-producing Multi-drug Resistant Klebsiella pneumoniae Isolates
by: Hüseyin Agah TERZİ, et al.
Published: (2020-12-01)

First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
by: Rahimzadeh M, et al.
Published: (2020-02-01)

In vitro activity of ceftolozane–tazobactam and ceftazidime–avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study
by: Hasan Cenk Mirza, et al.
Published: (2020-03-01)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021-01-01)

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
by: Thitima Kongnakorn, et al.
Published: (2019-12-01)

In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
by: Jean SS, et al.
Published: (2018-10-01)

Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres
by: Elizabeth B. Hirsch, et al.
Published: (2020-09-01)

Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
by: Liao CH, et al.
Published: (2019-03-01)

Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report
by: Alamri AM, et al.
Published: (2020-11-01)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
by: Marco Fiore, et al.
Published: (2020-07-01)

Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
by: Xing Tan, et al.
Published: (2019-07-01)

In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)
by: D. Piérard, et al.
Published: (2021-06-01)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020-01-01)

Resistance to ceftazidime–avibactam and underlying mechanisms
by: Yuhang Wang, et al.
Published: (2020-09-01)

Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria
by: Kozlov R.S., et al.
Published: (2018-02-01)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
by: Jeffrey C. Jolliff, et al.
Published: (2016-01-01)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients
by: Paolo E. Coppola, et al.
Published: (2020-12-01)

Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency
by: Katie Stokem, et al.
Published: (2018-01-01)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
by: Melissa D. Barnes, et al.
Published: (2018-12-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
by: Jocelyn Qi-Min Teo, et al.
Published: (2021-02-01)

Clinical characteristics and outcomes of patients with multidrug-resistant Gram-negative bacterial infections treated with ceftazidime/avibactam
by: Huan Kuang, et al.
Published: (2020-12-01)

Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?
by: Paola Bocanegra-Ibarias, et al.
Published: (2020-12-01)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
by: Dan Li, et al.
Published: (2021-09-01)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
by: Xiaoyan Cui, et al.
Published: (2020-06-01)

Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam
by: Xianggui Yang, et al.
Published: (2019-11-01)

A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam
by: Kıvanç ŞEREFHANOĞLU
Published: (2019-12-01)

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens
by: Golub A.V., et al.
Published: (2018-11-01)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019-01-01)

Real-world use of ceftolozane/tazobactam: a systematic literature review
by: Laura Puzniak, et al.
Published: (2021-04-01)

Monotherapy of ceftazidime–avibactam and ceftolozane–tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates

Similar Items

Similar Items